TY - JOUR
TI - Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study
AU - Quach, Hang
AU - Fernyhough, Liam
AU - Henderson, Ross
AU - Corbett, Gillian
AU - Baker, Bart
AU - Browett, Peter
AU - Blacklock, Hilary
AU - Forsyth, Cecily
AU - Underhill, Craig
AU - Cannell, Paul
AU - others
JO - British Journal of Haematology
PY - 2017
VL - 177
TODO - 3
SP - 441--448
PB - 
SN - 0007-1048, 1365-2141
TODO - null
TODO - null
TODO - null
ER -